Stockscreener 앱 받기
5.62%
시간 외 거래:
전일 마감가:
$149.22
열려 있는:
$149
하루 거래량:
2.25M
Relative Volume:
2.12
시가총액:
$9.41B
수익:
$12.82B
순이익/손실:
$936.34M
주가수익비율:
13.11
EPS:
10.74
순현금흐름:
$1.47B
1주 성능:
+28.80%
1개월 성능:
+22.76%
6개월 성능:
+10.19%
1년 성능:
-18.16%
1일 변동 폭
$139.54
$151.42
1주일 범위
$108.88
$151.42
52주 변동 폭
$101.00
$178.38
다비타 Stock (DVA) Company Profile
명칭
Davita Inc
전화
310-536-2668
주소
2000 16TH STREET, DENVER, CO
Compare DVA vs HCA, THC, FMS, UHS, ENSG
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DVA
Davita Inc
|
140.83 | 9.98B | 12.82B | 936.34M | 1.47B | 10.74 |
|
HCA
Hca Healthcare Inc
|
501.69 | 117.24B | 75.60B | 7.78B | 7.69B | 28.38 |
|
THC
Tenet Healthcare Corp
|
201.37 | 17.22B | 20.69B | 2.40B | 1.55B | 15.62 |
|
FMS
Fresenius Medical Care Ag Adr
|
24.08 | 14.12B | 21.23B | 924.30M | 2.22B | 1.2272 |
|
UHS
Universal Health Services Inc
|
218.56 | 13.53B | 16.08B | 1.20B | 1.06B | 17.82 |
|
ENSG
Ensign Group Inc
|
197.80 | 11.46B | 4.11B | 239.98M | 193.10M | 4.12 |
다비타 Stock (DVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-06 | 개시 | Barclays | Equal Weight |
| 2023-08-07 | 업그레이드 | UBS | Neutral → Buy |
| 2022-11-01 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-10-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-08-19 | 재개 | UBS | Buy |
| 2022-06-21 | 재확인 | BofA Securities | Underperform |
| 2021-09-10 | 개시 | Cowen | Market Perform |
| 2021-08-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-03-26 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-01-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-10-25 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2019-09-11 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-01-08 | 업그레이드 | UBS | Sell → Neutral |
| 2019-01-03 | 개시 | Deutsche Bank | Buy |
| 2018-12-14 | 개시 | Barclays | Overweight |
| 2018-11-28 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-11-16 | 개시 | UBS | Sell |
| 2018-11-08 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2018-09-13 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-01-04 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-12 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2017-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2017-12-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2017-11-08 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2016-12-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
다비타 주식(DVA)의 최신 뉴스
2 Warren Buffett Stocks to Buy Hand Over Fist in 2026 and 1 to Avoid - The Motley Fool
DaVita Dipped 6% After Big Run-Up: Why Analysts See a Path to $210 in 2026 - TIKR.com
DaVita (DVA) Surges as Top Healthcare Gainer in S&P 500 - GuruFocus
DaVita (DVA) Is Up 28.8% After Strong 2026 Guidance And Heavy BuybacksWhat's Changed - simplywall.st
Guidance Update: Will DaVita Inc stock benefit from M AMarket Risk Report & Weekly Chart Analysis and Guides - baoquankhu1.vn
DaVita, Elara deal could signal new take on kidney, home care - Modern Healthcare News
Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely - simplywall.st
Should Value Investors Buy DaVita (DVA) Stock? - Yahoo Finance
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term - Yahoo Finance
DaVita Links IKC Profitability With Elara Home Care To Recast Growth - Yahoo Finance
Here's why you should hold DaVita stock in your portfolio for now - MSN
DaVita stock price pops again as 2026 outlook fuels fresh Wall Street targets - TechStock²
UBS Raises Price Target for DaVita (DVA) to $190, Maintains Buy Rating | DVA Stock News - GuruFocus
DaVita Projects Significant EPS Growth Amid Strategic Expansion - StocksToTrade
DaVita stock price target raised to $190 from $186 at UBS on growth outlook - Investing.com Australia
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA) - The Globe and Mail
Why Is DaVita (DVA) Stock Rocketing Higher Today - The Globe and Mail
DVA Q4 Deep Dive: Clinical Initiatives and Integrated Care Drive Outlook Amid Margin Compression - The Globe and Mail
Dallas Team Featured as Litigator of the Week - Winston & Strawn
Research Alert: CFRA Maintains Hold View On Shares Of Davita Inc. - 富途牛牛
Is DaVita stock underperforming the Dow? - MSN
Ares, DaVita to invest in home health provider Elara Caring By Investing.com - Investing.com India
DaVita Home Care Partnership Puts Valuation And Risk Profile In Focus - Sahm
DaVita’s Q4 Earnings Triumph Sparks Market Interest - timothysykes.com
DaVita Inc. stock outperforms competitors on strong trading day - MarketWatch
DaVita (DVA) Shares Surge on Strong Q4 Results and Optimistic 20 - GuruFocus
DaVita Stock Surges as Q4 Earnings Exceed Expectations - StocksToTrade
DaVita Celebrates Strong Earnings as Strategic Investments Boost Future Outlook - timothysykes.com
Ares, DaVita Make Strategic Investment in Elara Caring - Hospice News
DaVita climbs as Q4 beat outshines Berkshire Hathaway insider sale - Seeking Alpha
Explore DaVita Within Dow Jones Industrial Average Healthcare Space - Kalkine Media
DaVita (DVA) Shares Surge Over 21% Amid Market Moves - GuruFocus
DaVita stock price jumps nearly 20% as 2026 profit outlook beats Street; what investors watch next - TechStock²
What Sent DaVita Stock Soaring On Tuesday? - Finviz
DaVita Inc Stock Soars 25% After DaVita Beats Q4 Results And Raises 2026 Outlook - Nasdaq
DaVita Stock Rallies On Profit Beat, Confident 2026 View - Benzinga
DaVita Stock Soars as Q4 Earnings and Strategy Surpass Expectations - StocksToTrade
Silver Surges Over 15%; Pfizer Earnings Top Views - Benzinga
Short Interest in DaVita Inc. (NYSE:DVA) Decreases By 14.2% - MarketBeat
DaVita’s Remarkable Financial Surge Surpasses Analysts’ Expectations - timothysykes.com
TD Cowen reiterates Hold rating on DaVita stock with $133 price target - Investing.com
DaVita (DVA) Soars Over 23% Amid Positive Market Movement - GuruFocus
DaVita: Some Success Is Possible, But Volatility Is Still Heavy (NYSE:DVA) - Seeking Alpha
DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand - TradingView
DaVita (NYSE:DVA) Shares Gap Up After Earnings Beat - MarketBeat
Davita Posts Upbeat Q4 Earnings, Joins Woodward, Terawulf And Other Big Stocks Moving Higher On Tuesday - Benzinga
Barclays Raises Price Target for DaVita (DVA) to $158 | DVA Stoc - GuruFocus
DaVita Q4 Revenue Up 10%; Announces Strategic Investment In Elara Caring - Nasdaq
DaVita Inc. (NYSE:DVA) Q4 2025 Earnings Call Transcript - Insider Monkey
DaVita rises on upbeat annual profit forecast - TradingView
Barclays Adjusts Price Target on DaVita to $158 From $143 - marketscreener.com
다비타 (DVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.86%
1.25%
자본화:
|
볼륨(24시간):